Jax DiEugenio

Adjuvant cemiplimab significantly cut recurrence risk and improved disease-free survival in high-risk CSCC, establishing a new standard of care.

Arlo-cel achieved a high ORR and CR rate with durable responses and favorable safety in relapsed/refractory multiple myeloma.

XS003 shows bioequivalence to nilotinib at half the dose with a reduced food effect for patients with CML.

Final DeFi trial results show sustained responses, improved PROs, and a stable safety profile with long-term nirogacestat in desmoid tumors.

Enfortumab vedotin plus pembrolizumab demonstrated meaningful first-line clinical activity in PD-L1–positive recurrent or metastatic HNSCC.

Adjuvant cemiplimab and placebo were associated with similar rates of second primary tumors in high-risk CSCC.

Fruquintinib plus sintilimab significantly extended progression-free survival in advanced RCC following first-line VEGFR TKI therapy.

Teclistamab plus daratumumab improved progression-free and overall survival in relapsed/refractory multiple myeloma after 1 to 3 lines of therapy.

A meta analysis found BTK inhibitors carry risks of hypertension, atrial fibrillation, and hemorrhage, underscoring the need for cardiovascular monitoring.

Kevin Elias, MD, discusses the role of olaparib in the management of ovarian cancer.

Ibrutinib plus rituximab showed a progression-free survival benefit vs standard chemoimmunotherapy in older patients with untreated mantle cell lymphoma.

ONO-4578 plus nivolumab and chemotherapy improved PFS in HER2-negative advanced gastric cancer.

Patients with MCL who relapsed after brexu-cel had poor survival outcomes, underscoring the need for effective post–CAR T-cell therapy strategies.

Experts in genitourinary oncology share key insights on the most anticipated data and abstracts expected to shape discussions at the 2025 ESMO Congress.

The FDA has issued a CRL for dasatinib, a next-generation formulation of a protein kinase inhibitor, for the treatment of patients with chronic myeloid leukemia.

A new drug application was submitted to Japan’s Ministry of Health, Labour and Welfare for T-DXd plus pertuzumab for HER2-positive breast cancer.

Paula Rodriguez-Otero, MD, discusses linvoseltamab’s potential role in the management of high-risk smoldering myeloma.

BTK inhibitor therapy improved PFS vs chemoimmunotherapy in NOTCH1-mutated CLL, highlighting the value of NOTCH1 screening to guide treatment selection.

Phase 2 data showed bevacizumab plus erlotinib active in papillary RCC, with 72% responses in HLRCC-associated and 35% in sporadic disease.

Multiple myeloma and non-Hodgkin lymphoma emerge as key hematology topics ahead of ESMO 2025, followed by MPNs and T-cell lymphoma.

A real-world analysis shows avelumab plus axitinib is safe and effective in advanced RCC.

Samir Parekh, MBBS, discusses monitoring rare CAR T-cell complications, anti-CCR4 therapy, and future research to improve safety and prevent secondary cancers.

The FDA approved Enoby and Xtrenbo, denosumab biosimilars referencing Prolia and Xgeva, respectively.

Samir Parekh, MD, discusses managing a rare T-cell lymphoma post BCMA CAR T-cell therapy and how CCR4-targeted treatment achieved durable remission.

The FDA has received a BLA seeking the approval of pivekimab sunirine for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm.

Trastuzumab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival vs trastuzumab emtansine in HER2-positive early breast cancer.

OncLive social media polls reveal which lung cancer abstracts are generating excitement ahead of the 2025 ESMO Congress.

OncLive social media polls reveal which prostate, kidney, and bladder cancer abstracts are generating excitement ahead of the 2025 ESMO Congress.

The FDA has removed the REMS program for vandetanib for the treatment of patients with medullary thyroid cancer.